N/A Completed N=1,718

Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

Hypertension · Diabetes · Death From Cardiovascular Disease · Myocardial Infarction

Source: ClinicalTrials.gov NCT01499511 ↗

Enrolled (actual)

1,718

Serious AEs

0.1%

Results posted

Dec 2019

Primary outcomePrimary: Number of Participants Who Have Died From Cardiovascular Disease Since the End of the ASCOT Study

Summary

ASCOT-10 is a follow-up study of surviving participants in the United Kingdom (UK)arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) which was conducted between 2000 and 2005.ASCOT's results showed substantial cardiovascular benefit from: 1) the use of a cholesterol lowering drug (atorvastatin) compared to placebo, and 2) the use of a blood-pressure lowering strategy based on amlodipine when compared to a strategy based on atenolol. ASCOT-10 will test the hypothesis that the ASCOT subjects who originally received Atorvastatin and those who received amlodipine based treatment will continue to show a cardiovascular benefit relative to those who did not, even though all the subjects have had access to optimal treatment in the interim.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Who Have Died From Cardiovascular Disease Since the End of the ASCOT Study	—	—
PRIMARY Number of Participants With Non Fatal Myocardial Infarction	35; 37	0.624
PRIMARY Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack)	29; 52	0.004 sig
SECONDARY Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial	322; 325	0.304
SECONDARY Number of Participants Who Have Undergone Coronary/Peripheral Re-vascularisation Procedures Since the End of the ASCOT Trial	39; 33	0.641
SECONDARY Number of Participants Who Have Required Renal Replacement Therapy (Dialysis or Kidney Transplant) Since the End of the ASCOT Trial	10; 9	0.915
SECONDARY Number of Participants Who Have Experienced a Transient Ischaemic Attack (TIA) Since the End of the ASCOT Trial	—	—

Eligibility Criteria

Inclusion Criteria

Surviving ASCOT participants from the participating UK sites

Exclusion Criteria

None

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01499511). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.